Mechanisms of antihyperglycemic effect of p-methoxycinnamic acid in normal and streptozotocin-induced diabetic rats

被引:53
作者
Adisakwattana, S
Roengsamran, S
Hsu, WH
Yibchok-Anun, S
机构
[1] Chulalongkorn Univ, Fac Vet Sci, Dept Pharmacol, Bangkok 10330, Thailand
[2] Chulalongkorn Univ, Fac Sci, Dept Chem, Res Ctr Bioorgan Chem, Bangkok 10330, Thailand
[3] Iowa State Univ, Dept Biomed Sci, Ames, IA 50011 USA
关键词
p-methoxycinnamic acid; diabetes; streptozotocin; carbohydrate metabolism;
D O I
10.1016/j.lfs.2005.04.073
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 [基础医学];
摘要
We investigated the antihyperglycernic effect of p-methoxycinnamic acid (p-MCA), a cinnamic acid derivative, on plasma glucose and insulin concentrations, activities of hepatic glucose-regulating enzymes and hepatic glycogen content in normal and streptozotocin (STZ)-induced diabetic rats. p-MCA (10 - 100 mg/kg, PO) dose-dependently decreased plasma glucose concentration in both normal and diabetic rats in the oral glucose tolerance test. To investigate the chronic effects of p-MCA on glucose metabolism, p-MCA (40 mg/kg, PO) was administered to normal and diabetic rats once a day for 4 weeks. p-MCA reduced plasma glucose concentration in diabetic rats, which was observed during the 4-week study. However, p-MCA treatment did not change plasma glucose concentrations in normal rats during the 4-week study. p-MCA also reduced the excessive activities of hepatic glucose-6-phosphatase, hepatic hexokinase, glucokinase and phosphofructokinase in diabetic rats and increased hepatic glycogen in these rats. In p-MCA-treated normal rats, there were no changes in the activities of hepatic glucose-regulating enzymes, hepatic glycogen and glucose-6-phosphate. Our findings suggested that p-MCA exert its antihyperglycernic effect by increasing insulin secretion and glycolysis, and by decreasing gluconeogenesis. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:406 / 412
页数:7
相关论文
共 39 条
[1]
Structure-activity relationships of trans-cinnamic acid derivatives on α-glucosidase inhibition [J].
Adisakwattana, S ;
Sookkongwaree, K ;
Roengsumran, S ;
Petsom, A ;
Ngamrojnavanich, N ;
Chavasiri, W ;
Deesamer, S ;
Yibchok-Anun, S .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (11) :2893-2896
[2]
The pharmacology of diabetic complications [J].
Altan, VM .
CURRENT MEDICINAL CHEMISTRY, 2003, 10 (15) :1317-1327
[3]
BARBERA A, 1994, J BIOL CHEM, V269, P20047
[4]
Genotoxicity of Streptozotocin [J].
Bolzán, AD ;
Bianchi, MS .
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2002, 512 (2-3) :121-134
[5]
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[6]
Oral combination therapy for type 2 diabetes [J].
Charpentier, G .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2002, 18 :S70-S76
[7]
Glucose-stimulated and self-limiting insulin production by glucose 6-phosphatase promoter driven insulin expression in hepatoma cells [J].
Chen, R ;
Meseck, M ;
McEvoy, RC ;
Woo, SLC .
GENE THERAPY, 2000, 7 (21) :1802-1809
[8]
Stimulatory effect of caffeic acid on α1A-adrenoceptors to increase glucose uptake into cultured C2C12 cells [J].
Cheng, JT ;
Liu, IM .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2000, 362 (02) :122-127
[9]
Control of glycogen deposition [J].
Ferrer, JC ;
Favre, C ;
Gomis, RR ;
Fernández-Novell, JM ;
García-Rocha, M ;
de la Iglesia, N ;
Cid, E ;
Guinovart, JJ .
FEBS LETTERS, 2003, 546 (01) :127-132
[10]
Fiske CH, 1925, J BIOL CHEM, V66, P375